Navigation Links
Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
Date:1/29/2008

tory markers, reducing fatigue (poor energy recovery) and the breakdown of muscle (post exercise wasting), as well as the lessening of free radical production (oxidative stress). The formula meets NCAA guidelines for use by collegiate athletes and is certified by The Banned Substances Control Group (BSCG) to contain no banned substances.

About Millennium:

Millennium's three proprietary, marketed products, which form the Company's Resurgex(R) Continuum of Care, include Resurgex Select(R), Resurgex(R), and Resurgex Plus(R). Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium is also recently developed a Surgex(TM) sports nutrition formula, clinically proven to address the nutritional concerns of the Professional, Olympic and amateur elite athletes. These athletes often experience similar symptoms post- workout to those battling immuno-compromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results o
'/>"/>

SOURCE Millennium Biotechnologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins
4. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
5. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
7. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
9. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. YMed, Inc. Successfully Completes First Clinical Cases With Innovative VascuTraK(TM) II PTA Dilatation Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , Indien, August 1, 2014 ... BioQuiddity Inc. gaben heute bekannt, vor kurzem ... Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen Eingriffen eine ... Gebiet der Europäischen Union und weiterer europäischer ... versehene und mit Ropivacain gefüllte OneDose ReadyfusOR ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif., July 31, 2014 IRIDEX Corporation ... the second quarter and six months ended June 28, 2014.  ... quarter of 2014, up 15% from $9.2 million in the ... the first quarter of 2014. Revenues for the first six ... million in the first six months of last year. ...
(Date:7/31/2014)... July 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... developments for the quarter ended June 30, 2014. ... 30, 2014 Revenue Total revenue for the quarter ended ... for the quarter ended June 30, 2013 primarily due to ... Total revenue for the six months ended ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28
... PHILADELPHIA, Jan. 5, 2011 ERT (Nasdaq: ... of technology and services to the pharmaceutical, biotechnology and ... Suicide Severity Rating Scale) solution facilitates compliance with the ... entitled "Suicidality: Prospective Assessment of Occurrence in Clinical Trials." ...
... Jan. 5, 2011 Cell Biosciences, Inc., a ... science researchers, today announced the launch of the ... imaging products, the FluorChem® M MultiFluor system. This ... fluorescent Western blots with key ease-of-use features aimed ...
Cached Medicine Technology:eC-SSRS Solution from ERT Facilitates Compliance with New FDA Guidance on Suicidality Assessment in Clinical Trials 2eC-SSRS Solution from ERT Facilitates Compliance with New FDA Guidance on Suicidality Assessment in Clinical Trials 3Cell Biosciences Launches New Platform for Multiplex Western Blot Detection 2
(Date:8/1/2014)... The "Antimicrobial Coatings Market by Type (Silver, ... Dioxide, and Zinc Omadine), Application (Indoor air/HVAC, Medical, ... Textiles, and others), & Geography (North America, Europe, ... to 2018" analyzes the Antimicrobial Coatings Market with ... the diverse geographical regions. , Browse 49 market ...
(Date:8/1/2014)... 1, 2014 (HealthDay News) -- Although many parents worry about ... a common choking hazard: food. Such was the ... cough after eating a handful of nuts. "At the ... if the coughing was related to his illness or choking," ... cold. A cashew had become lodged in his windpipe and ...
(Date:8/1/2014)... For years, proponents have praised breast-feeding as ... conducted by the Ohio State University, suggests that ... terms of their health and development, raising questions among ... their baby. So does this new research change the ... , chair of Pediatrics at Abington Memorial Hospital, not ...
(Date:8/1/2014)... 2014 (BRONX, NY) Scientists at Albert ... found that bacteria that aid in digestion help keep ... the journal Immunity , could yield new therapies ... of other disorders. , The research involved the intestinal ... of these microorganisms in promoting or preventing disease is ...
(Date:8/1/2014)... In today’s age, traditional learning methods are futile in ... methods need to be revamped, so that the necessary ... this age of the internet, online learning resources act ... management systems help in the planning, implementation, and assessment ... are proving to be very useful and this trend ...
Breaking Medicine News(10 mins):Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3Health News:'Normal' bacteria vital for keeping intestinal lining intact 2Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Learning Management System Market is Expected to Reach $5.13 Billion in 2018 - New Report by MicroMarket Monitor 4
... Dec. 13 (HealthDay News) -- In the aftermath of a ... the U.S. National Transportation Safety Board is recommending a nationwide ... devices, except in emergencies. According to media reports, the ... fatal pileup that occurred last year in Gray Summit, Mo. ...
... 14, 2011Caffeine is regarded by some as being a potent ... exercise performance. A range of expert opinions capture the scope ... in Journal of Caffeine Research , a quarterly peer-reviewed ... available online at www.liebertpub.com/jcr . Led by ...
... WASHINGTON -- A new Institute of Medicine report specifies ... Administration should require before allowing tobacco companies to sell ... of reducing the health risks of tobacco use. ... of a comprehensive strategy to lower tobacco-related death and ...
... an animal model is a difficult task, but Thomas ... Reporting in the Proceedings of the ... immunologists found that a specialized "human immune system" mouse model ... tick-borne infection known as relapsing fever, caused by the bacteria ...
... of its ongoing efforts to ensure safe, effective and ... joined the ABIM Foundation and eight other medical specialty ... choices by physicians and patients to improve health outcomes, ... dollars. The ACR will develop a list ...
... German . Compared to Neanderthals, modern humans have ... lobes and olfactory bulbs also suggest a combined use of ... of brain size is intimately linked to the evolution of ... independently evolved brains of roughly the same size but with ...
Cached Medicine News:Health News:U.S. Safety Board Urges Nationwide Ban on Drivers' Use of Cellphones 2Health News:New report identifies research needed on 'modified risk' tobacco products 2Health News:New report identifies research needed on 'modified risk' tobacco products 3Health News:Jefferson researchers mirror human response to bacterial infection and resolution in mice 2Health News:ACR in Choosing Wisely campaign to promote wise use of resources among physicians and patients 2Health News:Follow your nose 2
... is powerful, lightweight, easy ... soft, durable foam silicone ... covered by machine washable ... headband easily adjusts to ...
... is powerful, lightweight, easy ... soft, durable foam silicone ... covered by machine washable ... headband easily adjusts to ...
Solarc surgical headlight is durable, comfortable, lightweight and delivers the bright, white light expected from a xenon system, but at a fraction of the cost....
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Medicine Products: